HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria.
AIDS
; 36(1): 137-146, 2022 01 01.
Article
in En
| MEDLINE
| ID: mdl-34628443
ABSTRACT
OBJECTIVE:
This study was designed to provide information on the genetic diversity of HIV-1 and drug resistance mutations in Nigeria, as there is limited understanding of variants circulating in the country.METHODS:
We used an advanced next-generation sequencing platform, Primer ID, to investigate the presence of high and low abundance drug resistance mutations; characterize preexisting Integrase Strand Transfer Inhibitor (INSTI) mutations in antiretroviral therapy (ART)-experienced but dolutegravir-naive individuals; detect recent HIV-1 infections and characterize subtype diversity from a cohort of people with HIV-1 (PWH).RESULTS:
HIV-1 subtype analysis revealed the predominance of CRF02_AG and subtype G in our study population. At detection sensitivity of 30% abundance, drug resistance mutations (DRMs) were identified in 3% of samples. At a sensitivity level of 10%, DRMs were identified in 27.3% of samples. We did not detect any major INSTI mutation associated with dolutegravir-resistance. Only one recent infection was detected in our study population.CONCLUSION:
Our study suggests that dolutegravir-containing antiretroviral regimens will be effective in Nigeria. Our study also further emphasizes the high genetic diversity of HIV-1 in Nigeria and that CRF02_AG and subtype G are the dominant circulating forms of HIV-1 in Nigeria. These two circulating forms of the virus are largely driving the epidemic in the country.
Full text:
1
Database:
MEDLINE
Main subject:
HIV Infections
/
HIV-1
/
HIV Integrase Inhibitors
/
HIV Integrase
Type of study:
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
Africa
Language:
En
Journal:
AIDS
Journal subject:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Year:
2022
Type:
Article